Ernexa Therapeutics Inc. (ERNAW) Net margin 2016–2025
Ernexa Therapeutics Inc. (ERNAW) net profit margin by fiscal year — reported net income divided by reported revenue.
-2419.9%FY2025 · since FY2016: -11.9% → -2419.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -2419.9% | +63078.6 pp |
| FY2024 | -65498.5% | — |
| FY2021 | -2112.8% | -2076.0 pp |
| FY2020 | -36.8% | -28.0 pp |
| FY2019 | -8.8% | -7.6 pp |
| FY2018 | -1.2% | +3.6 pp |
| FY2017 | -4.8% | +7.1 pp |
| FY2016 | -11.9% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More ERNAW financial trends
ERNAW RevenueERNAW Net incomeERNAW Gross profitERNAW Gross marginERNAW Operating incomeERNAW Operating marginERNAW Operating cash flowERNAW Free cash flowERNAW Capital expendituresERNAW Return on equityERNAW Stock buybacksERNAW Dividends paidERNAW Total assetsERNAW Total liabilitiesERNAW Shareholders’ equityERNAW overview →